FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2865850863> ?p ?o ?g. }

• W2865850863 endingPage "288" @default.
• W2865850863 startingPage "282" @default.
• W2865850863 abstract "BackgroundDupuytren's disease is a common fibrotic condition of the hand that causes irreversible flexion contractures of the fingers, with no approved therapy for early stage disease. Our previous analysis of surgically-excised tissue defined tumour necrosis factor (TNF) as a potential therapeutic target. Here we assessed the efficacy of injecting nodules of Dupuytren's disease with a TNF inhibitor.MethodsPatients were randomised to receive adalimumab on one occasion in dose cohorts of 15 mg in 0.3 ml, 35 mg in 0.7 ml, or 40 mg in 0.4 ml, or an equivalent volume of placebo in a 3:1 ratio. Two weeks later the injected tissue was surgically excised and analysed. The primary outcome measure was levels of mRNA expression for α-smooth muscle actin (ACTA2). Secondary outcomes included levels of α-SMA and collagen proteins. The trial was registered with ClinicalTrial.gov (NCT03180957) and the EudraCT (2015-001780-40).FindingsWe recruited 28 patients, 8 assigned to the 15 mg, 12 to the 35 mg and 8 to the 40 mg adalimumab cohorts. There was no change in mRNA levels for ACTA2, COL1A1, COL3A1 and CDH11. Levels of α-SMA protein expression in patients treated with 40 mg adalimumab (1.09 ± 0.09 ng per μg of total protein) were significantly lower (p = 0.006) compared to placebo treated patients (1.51 ± 0.09 ng/μg). The levels of procollagen type I protein expression were also significantly lower (p < 0.019) in the sub group treated with 40 mg adalimumab (474 ± 84 pg/μg total protein) compared with placebo (817 ± 78 pg/μg). There were two serious adverse events, both considered unrelated to the study drug.InterpretationIn this dose-ranging study, injection of 40 mg of adalimumab in 0.4 ml resulted in down regulation of the myofibroblast phenotype as evidenced by reduction in expression of α-SMA and type I procollagen proteins at 2 weeks. These data form the basis of an ongoing phase 2b clinical trial assessing the efficacy of intranodular injection of 40 mg adalimumab in 0.4 ml compared to an equivalent volume of placebo in patients with early stage Dupuytren's disease.FundingHealth Innovation Challenge Fund (Wellcome Trust and Department of Health) and 180 Therapeutics LP." @default.
• W2865850863 created "2018-07-19" @default.
• W2865850863 creator A5009213464 @default.
• W2865850863 creator A5013780860 @default.
• W2865850863 creator A5015931406 @default.
• W2865850863 creator A5018156136 @default.
• W2865850863 creator A5023771684 @default.
• W2865850863 creator A5049261212 @default.
• W2865850863 creator A5056494354 @default.
• W2865850863 creator A5057580992 @default.
• W2865850863 creator A5058578454 @default.
• W2865850863 creator A5067212918 @default.
• W2865850863 creator A5068995535 @default.
• W2865850863 creator A5070919826 @default.
• W2865850863 creator A5075349431 @default.
• W2865850863 creator A5077042688 @default.
• W2865850863 creator A5079500211 @default.
• W2865850863 creator A5081276040 @default.
• W2865850863 creator A5085706080 @default.
• W2865850863 date "2018-07-01" @default.
• W2865850863 modified "2023-10-02" @default.
• W2865850863 title "Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial" @default.
• W2865850863 cites W1505584712 @default.
• W2865850863 cites W2045142779 @default.
• W2865850863 cites W2048826128 @default.
• W2865850863 cites W2049430789 @default.
• W2865850863 cites W2050092983 @default.
• W2865850863 cites W2067057226 @default.
• W2865850863 cites W2068608716 @default.
• W2865850863 cites W2081378978 @default.
• W2865850863 cites W2082908125 @default.
• W2865850863 cites W2109381471 @default.
• W2865850863 cites W2110936138 @default.
• W2865850863 cites W2115345891 @default.
• W2865850863 cites W2118160944 @default.
• W2865850863 cites W2133633410 @default.
• W2865850863 cites W2139210909 @default.
• W2865850863 cites W2144996452 @default.
• W2865850863 cites W2149065814 @default.
• W2865850863 cites W2151430869 @default.
• W2865850863 cites W2157610944 @default.
• W2865850863 cites W2166815562 @default.
• W2865850863 cites W2168467581 @default.
• W2865850863 cites W2200832510 @default.
• W2865850863 cites W2315207259 @default.
• W2865850863 cites W2467159661 @default.
• W2865850863 cites W2511517123 @default.
• W2865850863 cites W2513091910 @default.
• W2865850863 cites W2623581215 @default.
• W2865850863 cites W2753316804 @default.
• W2865850863 cites W2753367289 @default.
• W2865850863 doi "https://doi.org/10.1016/j.ebiom.2018.06.022" @default.
• W2865850863 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6085556" @default.
• W2865850863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29983350" @default.
• W2865850863 hasPublicationYear "2018" @default.
• W2865850863 type Work @default.
• W2865850863 sameAs 2865850863 @default.
• W2865850863 citedByCount "33" @default.
• W2865850863 countsByYear W28658508632018 @default.
• W2865850863 countsByYear W28658508632019 @default.
• W2865850863 countsByYear W28658508632020 @default.
• W2865850863 countsByYear W28658508632021 @default.
• W2865850863 countsByYear W28658508632022 @default.
• W2865850863 countsByYear W28658508632023 @default.
• W2865850863 crossrefType "journal-article" @default.
• W2865850863 hasAuthorship W2865850863A5009213464 @default.
• W2865850863 hasAuthorship W2865850863A5013780860 @default.
• W2865850863 hasAuthorship W2865850863A5015931406 @default.
• W2865850863 hasAuthorship W2865850863A5018156136 @default.
• W2865850863 hasAuthorship W2865850863A5023771684 @default.
• W2865850863 hasAuthorship W2865850863A5049261212 @default.
• W2865850863 hasAuthorship W2865850863A5056494354 @default.
• W2865850863 hasAuthorship W2865850863A5057580992 @default.
• W2865850863 hasAuthorship W2865850863A5058578454 @default.
• W2865850863 hasAuthorship W2865850863A5067212918 @default.
• W2865850863 hasAuthorship W2865850863A5068995535 @default.
• W2865850863 hasAuthorship W2865850863A5070919826 @default.
• W2865850863 hasAuthorship W2865850863A5075349431 @default.
• W2865850863 hasAuthorship W2865850863A5077042688 @default.
• W2865850863 hasAuthorship W2865850863A5079500211 @default.
• W2865850863 hasAuthorship W2865850863A5081276040 @default.
• W2865850863 hasAuthorship W2865850863A5085706080 @default.
• W2865850863 hasBestOaLocation W28658508631 @default.
• W2865850863 hasConcept C126322002 @default.
• W2865850863 hasConcept C127607297 @default.
• W2865850863 hasConcept C141071460 @default.
• W2865850863 hasConcept C142724271 @default.
• W2865850863 hasConcept C17991360 @default.
• W2865850863 hasConcept C204787440 @default.
• W2865850863 hasConcept C27081682 @default.
• W2865850863 hasConcept C2780132546 @default.
• W2865850863 hasConcept C503630168 @default.
• W2865850863 hasConcept C71924100 @default.
• W2865850863 hasConcept C90924648 @default.
• W2865850863 hasConceptScore W2865850863C126322002 @default.
• W2865850863 hasConceptScore W2865850863C127607297 @default.
• W2865850863 hasConceptScore W2865850863C141071460 @default.
• W2865850863 hasConceptScore W2865850863C142724271 @default.

• next